Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Antonio M. Risitano, Serena Marotta, Patrizia Ricci, Luana Marano, Camilla Frieri, Fabiana Cacace, Michela Sica, Austin Kulasekararaj, Rodrigo T. Calado, Phillip Scheinberg, Rosario Notaro, Regis Peffault de Latour
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2019-06-01
coleção:	Frontiers in Immunology
Assuntos:	paroxysmal nocturnal hemoglobinuria intravascular hemolysis extravascular hemolysis complement inhibition eculizumab ravulizumab
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fimmu.2019.01157/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!